The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin,
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The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin, 1-benzyl-2,4,6-tribromomelatonin, and 2,4,6,7-tetrabromomelatonin) and then examined the effects of these chemicals on osteoclasts and osteoblasts. All bromomelatonin derivatives, as well as melatonin, had an inhibitory action on osteoclasts. In particular, 1-benzyl-2,4,6-tribromomelatonin (benzyl-tribromomelatonin) possessed a stronger activity than melatonin. At an in vitro concentration of 10 -10 M, benzyl-tribromomelatonin still
Introduction
Melatonin, N-acetyl-5-methoxytryptamine, is a secretory product of the vertebrate pineal gland which is synthesized during darkness and exhibits a conspicuous circadian rhythm [1, 2] . In mammals including man, nighttime melatonin levels progressively drop throughout life [3, 4] , and, as a result, nocturnal melatonin levels in older individuals are much lower than they are in younger individuals [5] . Several reports indicate that melatonin is involved in the regulation of calcium homeostasis and bone metabolism. For example, melatonin prevents phototherapy-induced hypocalcemia in newborn rats [6] . On the basis of these reports, the effect of melatonin on bone metabolism was recently examined using the cell line of osteoblasts [7] [8] [9] . An interaction between osteoclasts and osteoblasts has been recently noted in mammals and it is necessary to consider both their actions [10, 11] . In addition, the receptor activator of NF-κB (RANK) and the receptor activator of the NF-κB ligand (RANKL) have been identified in osteoclasts and osteoblasts, respectively [12] . It was found that osteoclasts are activated by binding RANKL to RANK and that multi-nucleolus osteoclasts (active type of osteoclasts) are then induced [12] . The bone complex includes osteoblasts, osteoclasts, and the bone matrix. Therefore, a co-culture of these components is required; however, few techniques have been developed to accomplish this goal.
The teleost scale is a calcified tissue that contains osteoclasts and osteoblasts [13] [14] [15] . In the scale as well as in mammalian bone, components of the bone matrix including type I collagen [16] , bone γ-carboxyglutamic acid protein [17] , and osteonectin [18] , are present.
Hydroxyapatite also exists in the scale [19] . The scales of teleosts contain as much as 20% of the total body calcium and are a functional internal calcium reservoir during periods of increased calcium demand, such as sexual maturation and starvation [13, [20] [21] [22] . Thus, there are many similarities between the teleost scale and mammalian membrane bone.
Considering these findings, we recently developed a new in vitro assay system using the teleost scale [23, 24] . This system can simultaneously detect the activities of both osteoclasts and osteoblasts with tartrate-resistant acid phosphatase (TRAP) and alkaline phosphatase (ALP) as respective markers. In mammals, also, the effects of hormones on osteoclasts and osteoblasts have been investigated using the same bioactive markers [25, 26] . Furthermore, we detected the respective enzyme activity from individual scales by transferring each scale into a well of a 96-well microplate and directly incubating it with the substrate.
Using this in vitro assay system, our previous report demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities [24] . This was the first report related to the function of melatonin in osteoclasts and on the inhibitory effect of melatonin in osteoblasts in any vertebrate species. The finding suggested that melatonin may directly regulate bone metabolism.
It is well documented that many cells possess membrane melatonin receptors [27] [28] [29] .
However, there is no report regarding the effects of melatonin derivatives on osteoclasts and osteoblasts. In the present study, we synthesized novel bromomelatonin derivatives and investigated their effects on osteoclastic and osteoblastic activities because 2-bromomelatonin is known to have a higher affinity for the melatonin receptor than melatonin itself in mammals [30] [31] [32] . Also, the estrogen receptor, which is related to osteoblastic growth and differentiation [33] [34] [35] , was recently found to be associated with scales and shown to have a co-relationship with osteoblastic activity [36] . Thus, the mRNA expression of the estrogen receptor (ER) was analyzed using the reverse transcription-polymerase chain reaction (RT-PCR) method as an osteoblastic marker.
Materials and Methods

Animals
A previous study [23] indicated that the sensitivity for calcemic hormones was higher in mature female teleosts than in mature males. Therefore, mature female goldfish (Carassius auratus) (N=16) (40.5 ± 1.5 g) were purchased from a commercial source (Higashikawa Fish Farm, Yamatokoriyama, Japan) and used for the in vitro scale assay and mRNA analysis by RT-PCR. The fish were kept under usual conditions before the onset of the experiments. All experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of Kanazawa University.
Synthesis of bromomelatonin derivatives
Bromination of melatonin [37, 38] (1) with 0.9 mol eq. of Br 2 in AcOH in the presence of NaOAc afforded 2-bromomelatonin (2a) and 2,4-dibromomelatonin (2b) in 28 and 20%
yields, respectively, in addition to a 51% yield of unreacted 1 (Fig. 1) . The same reaction with 3 mol eq. of Br 2 exclusively provided 2,4,6-tribromomelatonin (3) in 94% yield. The measurement of TRAP and ALP activities has been described by Suzuki and Hattori [24] . The procedure for the TRAP measurement is as follows. Each scale was transferred to its own well in a 96-well microplate after being weighted. An aliquot of 200 µl of 10 mM para-nitrophenyl-phosphate and 20 mM tartrate in a 0.1 M sodium acetate buffer (pH 5.3) was added to each well. Then, this plate was incubated at 20 °C for 60 min while being shaken.
After incubation, the reaction was stopped by adding 50 µl of a 3 N NaOH-20 mM EDTA solution. One hundred and fifty µl of the colored solution was transferred to a new plate, and the absorbance was measured at 405 nm. The absorbance was converted to the amount of produced para-nitrophenol (pNP) using a standard curve for pNP.
The detection of ALP was the only change in the buffer system. ALP activities were measured using an alkaline buffer (100 mM Tris-HCl, pH 9.5; 1 mM MgCl 2 ; 0.1 mM ZnCl 2 ).
Other conditions were the same as for the measurement of the TRAP activity.
Changes in ER mRNA expression and osteoclastic and osteoblastic activities in the melatonin-and benzyl-tribromomelatonin-treated goldfish scales after 6 h of culture Scales were collected from goldfish under anesthesia with MS-222. To examine changes in ER mRNA expression in response to the most effective bromomelatonin, scales were incubated for 6 h in MEM (containing antibiotic and 20 mM HEPES) supplemented with benzyl-tribromomelatonin (10 -7 M), and the results were compared with those from melatonin (10 -7 M). After incubation, the scales were frozen at -80 °C for mRNA analysis, while the others were used in TRAP and ALP analyses using the methods previously described.
Total RNAs were prepared from goldfish scales using a total RNA isolation kit for fibrous tissue (Qiagen GmbH, Hilden, Germany). Complimentary DNA synthesis was performed using a kit (Qiagen GmbH). PCR was carried out with Taq The conditions for PCR amplification were denaturation for 0.5 min at 96 °C, annealing for 1 min at 60 °C, and extension for 2 min at 72 °C followed by a single cycle at 72 °C for 30 min.
The numbers of cycles for amplification in ER and β-actin cDNAs were determined by ensuring that PCR amplification was at submaximum and the intensity of the band corresponded exactly to the amount of starting material. The PCR products were analyzed on a 2.5% NuSive GTG agarose gel (FMC BioProducts, Rockland, ME, USA) and stained with ethidium bromide. The band densities were estimated using a computer program (Image J).
The ER mRNA level was normalized to the β-actin mRNA level. Considering the variance of scales among individual goldfish, the relative ratios of the melatonin/control and the benzyl-tribromomelatonin/control were then calculated. These experiments were performed using five goldfish for the statistical analysis.
Statistical analysis
The statistical significance was assessed by two-way or one-way ANOVA followed by the Dunnett test. The data for the ER mRNA level were analyzed using the paired t-test. The selected significance level was P<0.05.
Results
The results for osteoclasts are shown in figure 3 . Melatonin (10 -8 , 10 -6 , and 10 -4 M) suppressed osteoclastic activity. For 2-bromomelatonin and 2,4,6,7-tetrabromomelatonin, the inhibitory action was less than that of melatonin, at least under the present conditions. On the other hand, the strength of suppression by tribromomelatonin derivatives in osteoclasts was similar to that of melatonin. Figure 4 shows the results regarding osteoblasts. Melatonin inhibited osteoblastic activity.
However, all bromomelatonin derivatives have a promotional action of osteoblasts. In particular, benzyl-tribromomelatonin possessed the strongest activity for osteoblasts.
Therefore, we analyzed the detailed effects of this chemical on the scale osteoclasts and osteoblasts and compared them with those of melatonin. by two-way ANOVA analysis. Benzyl-tribromomelatonin has a stronger activity in osteoclasts than did melatonin. This inhibitory action of the derivative was still effective at 10 -10 M after 6 h of incubation compared with control (Fig.5A ). In addition, benzyl-tribromomelatonin activated osteoblasts (10 -9 to 10 -6 M) after 6 h of incubation, while melatonin (10 -8 to 10 -6 M) suppressed osteoblastic activity (Fig.6A) . The action of these chemicals on osteoclasts and osteoblasts after 18 h incubation was similar to that after 6 h incubation.
The typical pattern of PCR products is indicated in figure 7 . After 6 h of incubation, the expression of ER mRNA in melatonin (10 -7 M)-treated scales did not change from those of control scales; however, benzyl-tribromomelatonin (10 -7 M) increased ER mRNA expression.
The relative ratios of the melatonin/control and the benzyl-tribomelatonin/control were 0.912 ± 0.055 and 1.320 ± 0.101, respectively. A statistically significant difference (P<0.01) between control scales and benzyl-tribromomelatonin-treated scales was obtained. There was no band without reverse transcriptase (data not shown). however, benzyl-tribromomelatonin increased osteoblastic activities, while melatonin suppressed them.
Discussion
Since melatonin functions to suppress the activities of osteoclasts and osteoblasts [24] , we were interested in an indole molecule that would function to activate osteoblasts and suppress osteoclasts concurrently. For this purpose, we developed a simple, economical, and practical synthetic method starting from tryptamine, as reported previously [37, 38] , since the eight synthetic routes for melatonin so far developed have been ineffective [38, 42] . With melatonin in hand, we examined its halogenation under various reaction conditions with reagents such as chlorine gas, NCS, bromine, NBS, and Br 2 -AcOH in vain. We finally succeeded in identifying the regioselective tribromination of melatonin, culminating in the formation of a new 2,4,6-tribromomelatonin utilizing Br 2 -AcOH-NaOAc, as indicated in the present paper (Fig. 1) . Using this reaction, tetrabromomelatonin can also be synthesized (Fig.   1 ). In addition, novel tribromomelatonin derivatives were obtained as a result of the introduction of appropriate appendages, such as allyl, benzyl, and propargyl groups, onto the 1-position of tribromomelatonin. In the present study, we indicate that these bromomelatonin molecules have the ability to activate osteoblasts and suppress osteoclasts (Figs. 3-6 , Table 1 ).
This study is the first to demonstrate that bromomelatonins influence bone metabolism.
In osteoclasts, the suppressive action of 2-bromomelatonin and 2,4,6,7-tetrabromomelatonin was less strong than that of melatonin when the activities of these chemicals were compared at the concentrations of 10 -8 , 10 -6 , and 10 -4 M, as shown in figure 3 . On the other hand, the strength of suppression by tribromomelatonin derivatives in osteoclasts was similar to that of melatonin (Fig. 3) . Thus, the location of the bromine may be important for osteoclastic activity. We presume that melatonin receptors are located on osteoclast membranes since this receptor is detected on the mammalian monocytes [43], which are related to osteoclastic progenitors. In our previous study, we showed that the inhibitory action of melatonin in osteoclasts was faster than that in osteoblasts [24] .
Bromomelatonin increased osteoblastic activity, although melatonin suppressed it (Fig. 4) .
Also, benzyl-tribromomelatonin (10 -9 to 10 -6 M) activated osteoblasts at 6 h of incubation, while melatonin (10 -8 to 10 -6 M) suppressed osteoblastic activity at the same incubation time (Fig. 6 ). It seems that another receptor for bromomelatonin exists in osteoblasts.
Bromomelatonin derivatives might bind to this receptor and activate osteoblastic activity. In fact, a different action of melatonin and melatonin-related substances has been reported [44] [45] [46] . In the present study, all bromomelatonin derivatives almost equally promoted osteoblastic activity, although osteoclastic activities were changed by the location of the bromine. The results strongly indicate that bromomelatonin binds to an unknown receptor and promotes osteoblastic activity. Therefore, the mechanism of bromomelatonin in osteoblasts seems to be different from that in osteoclasts. In the response of osteoblasts to melatonin, inconsistent results have been reported. In an in vitro culture using the cell line of osteoblasts, osteoblastic activity increased by melatonin treatment [7, 8] while melatonin suppressed osteoblastic activity in an in vivo experiment using ovariectomized rats [47] as well as in our scale in vitro co-culture system of osteoblasts and osteoclasts. Furthermore, high endogeneous levels of melatonin correlate with low levels of bone forming markers (i.e. ALP and carboxyterminal propeptide of type I collagen) in male Wistar rats [48] . Plans are underway to examine the characterization of binding for melatonin and bromomelatonin derivatives using both goldfish scale and mammalian osteoblastic cell lines. This may contribute elucidation of the osteoblastic response to melatonin.
The mRNA expression of the ER (an osteoblastic marker) in the benzyl-tribromomelatonin-treated scales increased over the value of the control (Fig. 7) . In the goldfish used in ER mRNA analysis, benzyl-tribromomelatonin activated osteoblasts (Table 1 ). Our data indicate that bromomelatonin has a different action in osteoblasts than that of melatonin. In the case of osteoclasts, as described above, tribromomelatonin has the same inhibitory action as does melatonin (Fig. 3) . Therefore, tribromomelatonin has potential as a beneficial drug for bone diseases. It is well known that calcitonin, a 32-amino acid peptide hormone, has a hypocalcemic action and that calcitonin can mineralize bones by suppressing the activities of osteoclasts. This drug is useful for the treatment of human osteoporosis [49] [50] [51] . We recently obtained evidence that the strength of the inhibitory action of melatonin on scale osteoclasts was almost equal to that of salmon and eel calcitonins (N. Suzuki, personal communication). In addition, the present study indicates that the inhibitory strength of benzyl-tribromomelatonin on osteoclasts is higher than that of melatonin (Fig. 5) . In ovariectomized rats, melatonin has an inhibitory effect for urinary deoxypyridinoline as a marker of bone resorption, but it did not influence bone mineral density [52] . Thus, we believe that bromomelatonin derivatives have the potential to increase bone mineral density and that these chemicals have potential for use as benefical drugs for bone diseases such as osteoporosis. 
